Literature DB >> 1120316

Physiological disposition of pentobarbital in tumor-bearing mice.

W T Beck, H G Mandel, S Fabro.   

Abstract

Pentobarbital depressed macromolecular synthesis in Ehrlich ascites cells in vitro, and this depression was proportional to a decrease in oxygen consumption. However, survival time of animals bearing Ehrlich ascites cells was unaffected by pentobarbital. The acute toxicity of the drug was greatly enhanced by the presence of the tumor. Sleeping time was prolonged in mice carrying the following tumors: Ehrlich ascites, Sarcoma 180 ascites, and Yancy plasma cell solid. Seven-day Ehrlich ascites tumor-bearing animals treated with pentobarbital slept about three times longer than normal mice, but both groups awoke at the same plasma levels of the unbound drug. The plasma half-life of unchanged pentobarbital was about four times as long in tumor-bearing mice as it was in controls. No qualitative difference in catabolism other than rate was detected. Renal excretion of unchanged pentobarbital in tumor-bearing animals was 50% of control animals during the first 4 hr. In tumor-bearing mice the sleeping time of the nonmetabo ble barbiturate, barbital, was identical with that in normal animals. These data suggest that the tumor affected mainly pentobarbital metabolism. Tumor-bearing mice still responded to the pharmacological challenge of phenobarbital with the apparent induction of drug metabolizing enzymes. The prolonged pentobarbital sleeping time in tumor-bearing mice required the development of some type of tumor-host relationship.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1120316

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.

Authors:  B A Teicher; D Chatterjee; J T Liu; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse.

Authors:  G Powis; R N Harris; P J Basseches; K S Santone
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Increase in the gastrointestinal absorption and in tissue storage of cyclophosphamide in L-1210 leukaemic mice at an advanced stage of the disease.

Authors:  J G Lavigne; A Barry; C D'Auteuil; J M Delâge
Journal:  Br J Cancer       Date:  1975-12       Impact factor: 7.640

4.  P-aminosalicylate metabolism in cancer patients sensitive and resistant to chemotherapy.

Authors:  J G Lavigne; A Barry; C d'Auteuil; J M Delage
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.